Comparative Pharmacology
Head-to-head clinical analysis: MYSOLINE versus OXCARBAZEPINE EXTENDED RELEASE TABLETS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYSOLINE versus OXCARBAZEPINE EXTENDED RELEASE TABLETS.
MYSOLINE vs OXCARBAZEPINE EXTENDED RELEASE TABLETS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, inhibiting repetitive firing of action potentials, and reducing the propagation of synaptic impulses. Also modulates calcium channels and enhances potassium conductance.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
Initial: 300 mg orally twice daily. Increase by up to 600 mg/day at weekly intervals. Target maintenance: 1200-2400 mg/day in two divided doses. Extended-release tablets are dosed once daily: initial 600 mg, titrate weekly by 600 mg to maintenance 1200-2400 mg once daily.
None Documented
None Documented
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Oxcarbazepine: ~2 hours (not clinically relevant due to rapid conversion to MHD). MHD: ~9 hours (steady-state achieved in 2-3 days).
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Renal: ~70% (mainly as glucuronide conjugates of MHD and oxcarbazepine, with <1% unchanged oxcarbazepine and ~27% unchanged MHD). Fecal: <1%.
Category C
Category C
Anticonvulsant
Anticonvulsant